title: Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma.
authors.affiliation: Hospital Universitario de Salamanca, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain. emocio@usal.es.
authors.forename: Enrique M
authors.initials: EM
authors.lastname: Ocio
authors.affiliation: Hospital Universitario Germans Trias I Pujol, Badalona, Spain.
authors.forename: Albert
authors.initials: A
authors.lastname: Oriol
authors.affiliation: Hospital Clínico de Barcelona, Institut d'Investigacions Biomediques Auguust Pi I Sunyer, Barcelona, Spain.
authors.forename: Joan
authors.initials: J
authors.lastname: Bladé
authors.affiliation: Hospital Clínico Universitario de Valencia, Valencia, Spain.
authors.forename: Ana I
authors.initials: AI
authors.lastname: Teruel
authors.affiliation: Hospital Universitario Virgen del Rocío, Sevilla, Spain.
authors.forename: Jesus
authors.initials: J
authors.lastname: Martín
authors.affiliation: Hospital Dr. Peset and Universidad Católica San Vicente Mártir, Valencia, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: de la Rubia
authors.affiliation: Hospital Universitario de Salamanca, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain.
authors.forename: Norma C
authors.initials: NC
authors.lastname: Gutiérrez
authors.affiliation: PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain.
authors.forename: José
authors.initials: J
authors.lastname: Rodríguez Díaz-Pavón
authors.affiliation: PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain.
authors.forename: Sara
authors.initials: S
authors.lastname: Martínez González
authors.affiliation: PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain.
authors.forename: Cinthya
authors.initials: C
authors.lastname: Coronado
authors.affiliation: PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain.
authors.forename: Eva M
authors.initials: EM
authors.lastname: Fernández-García
authors.affiliation: PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain.
authors.forename: Mariano
authors.initials: M
authors.lastname: Siguero Gómez
authors.affiliation: PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Fernández-Teruel
authors.affiliation: Clínica Universidad de Navarra, Centro de Investigaciones Médicas Aplicadas (CIMA), IDISNA, Pamplona, Spain.
authors.forename: Jesus
authors.initials: J
authors.lastname: San Miguel
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012008:Recurrence; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; C500383:PM 00104; D044005:Tetrahydroisoquinolines
keywords: PM00104; dexamethasone; multiple myeloma; phase I/II